Direct comparison
Retatrutid vs Survodutid
How Retatrutid and Survodutid compare on mechanism, evidence and legal status — factual, no recommendations.
| Retatrutid | Survodutid | |
|---|---|---|
| Class | GLP-1 analog | GLP-1 analog |
| Evidence level | early clinical studies | early clinical studies |
| Legal status (DE) | not approved | not approved |
| WADA-listed | No | No |
| Molar mass | 4731.33 Da | 4232 Da |
| Studies cited | 2 | 2 |
| Research areas | Metabolism | Metabolism |
Retatrutid
Retatrutide is a triple agonist at GIP, GLP-1 and glucagon receptors (GGG agonist).
Full Retatrutid profileSurvodutid
Survodutide is a dual agonist at glucagon and GLP-1 receptors.
Full Survodutid profileImportant notice
This site is intended solely for factual, scientifically oriented information about peptides. It does not constitute medical advice, does not replace a consultation with a doctor and contains no recommendations for use in humans.
This site does not sell any substances and names no sources for unapproved substances. For medical questions, please consult qualified medical professionals.